405 related articles for article (PubMed ID: 7707109)
21. Selection and expansion of peripheral blood CD34+ cells in autologous stem cell transplantation for breast cancer.
Williams SF; Lee WJ; Bender JG; Zimmerman T; Swinney P; Blake M; Carreon J; Schilling M; Smith S; Williams DE; Oldham F; Van Epps D
Blood; 1996 Mar; 87(5):1687-91. PubMed ID: 8634412
[TBL] [Abstract][Full Text] [Related]
22. Ifosfamide, carboplatin, and etoposide plus granulocyte-macrophage colony-stimulating factor: a phase I study with apparent activity in non-small-cell lung cancer.
Krigel RL; Palackdharry CS; Padavic K; Haas N; Kilpatrick D; Langer C; Comis R
J Clin Oncol; 1994 Jun; 12(6):1251-8. PubMed ID: 8201386
[TBL] [Abstract][Full Text] [Related]
23. A dose intensity study of FLAC (5-fluorouracil, leucovorin, doxorubicin, cyclophosphamide) chemotherapy and Escherichia coli-derived granulocyte-macrophage colony-stimulating factor (GM-CSF) in advanced breast cancer patients.
O'Shaughnessy JA; Denicoff AM; Venzon DJ; Danforth D; Pierce LJ; Frame JN; Bastian A; Ghosh B; Goldspiel B; Miller L
Ann Oncol; 1994 Oct; 5(8):709-16. PubMed ID: 7826903
[TBL] [Abstract][Full Text] [Related]
24. Phase I/II trial of cyclophosphamide, mitoxantrone, and escalated doses of carboplatin supported by peripheral-blood stem cells in women with metastatic breast cancer.
Patnaik A; MacKinnon J; Goss P; Nagy T; Stewart K; Keating A; Crump M
J Clin Oncol; 2000 Jun; 18(12):2363-8. PubMed ID: 10856095
[TBL] [Abstract][Full Text] [Related]
25. [High-dosage chemotherapy and the autologous transplantation of peripheral hematopoietic progenitor cells in breast cancer: the initial results, analysis of toxicity and the necessary support means].
Sola Rocabert C; Mesía R; Mendoza L; Tabernero JM; Amill B; Maroto P; Bellet M; Ojeda B; Alonso MC; Verger G
Med Clin (Barc); 1995 Oct; 105(11):407-11. PubMed ID: 7475451
[TBL] [Abstract][Full Text] [Related]
26. High-dose chemotherapy with tandem autologous transplantation as part of the initial therapy for aggressive non-Hodgkin's lymphoma.
Ballestrero A; Clavio M; Ferrando F; Gonella R; Garuti A; Sessarego M; Ghio R; Gobbi M; Patrone F
Int J Oncol; 2000 Nov; 17(5):1007-13. PubMed ID: 11029505
[TBL] [Abstract][Full Text] [Related]
27. Randomized double-blind prospective trial to evaluate the effects of sargramostim versus placebo in a moderate-dose fluorouracil, doxorubicin, and cyclophosphamide adjuvant chemotherapy program for stage II and III breast cancer.
Jones SE; Schottstaedt MW; Duncan LA; Kirby RL; Good RH; Mennel RG; George TK; Snyder DA; Watkins DL; Denham CA; Hoyes FA; Rubin AS
J Clin Oncol; 1996 Nov; 14(11):2976-83. PubMed ID: 8918495
[TBL] [Abstract][Full Text] [Related]
28. Double dose-intensive chemotherapy with autologous stem-cell support for metastatic breast cancer: no improvement in progression-free survival by the sequence of high-dose melphalan followed by cyclophosphamide, thiotepa, and carboplatin.
Ayash LJ; Elias A; Schwartz G; Wheeler C; Ibrahim J; Teicher BA; Reich E; Warren D; Lynch C; Richardson P; Schnipper L; Frei E; Antman K
J Clin Oncol; 1996 Nov; 14(11):2984-92. PubMed ID: 8918496
[TBL] [Abstract][Full Text] [Related]
29. CD34+ cell dose requirements for rapid engraftment in a sequential high-dose chemotherapy regimen of paclitaxel, melphalan, and cyclophosphamide, thiotepa, and carboplatin (CTCb) with PBPC support in metastatic breast cancer.
Papadopoulos KP; Ayello J; Reiss RF; Troxel A; Kaufman E; Vahdat LT; Antman KH; Hesdorffer CS
J Hematother Stem Cell Res; 1999 Aug; 8(4):357-63. PubMed ID: 10634173
[TBL] [Abstract][Full Text] [Related]
30. The impact of induction duration and the number of high-dose cycles on the long-term survival of women with metastatic breast cancer treated with high-dose chemotherapy with stem cell rescue: an analysis of sequential phase I/II trials from the Dana-Farber/Beth Israel STAMP program.
Elias AD; Ibrahim J; Richardson P; Avigan D; Joyce R; Reich E; McCauley M; Wheeler C; Frei E
Biol Blood Marrow Transplant; 2002; 8(4):198-205. PubMed ID: 12017145
[TBL] [Abstract][Full Text] [Related]
31. A novel high-dose chemotherapy protocol with autologous hematopoietic rescue in patients with metastatic breast cancer or recurrent non-Hodgkin's lymphoma.
Fontelonga A; Kelly AJ; MacKintosh FR; Hall S; Monroe P; Wilson GS; Shaft D; Ruthven A; Ascensao JL
Bone Marrow Transplant; 1997 May; 19(10):983-8. PubMed ID: 9169642
[TBL] [Abstract][Full Text] [Related]
32. Sequential interleukin-3 and granulocyte-colony stimulating factor prior to and following high-dose etoposide and cyclophosphamide: a phase I/II trial.
Bernstein SH; Fay JP; Christiansen NP; Pinero L; Shah D; Stephan M; Herzig GP
Clin Cancer Res; 1997 Sep; 3(9):1519-26. PubMed ID: 9815838
[TBL] [Abstract][Full Text] [Related]
33. Optimal timing for collections of blood progenitor cells following induction chemotherapy and granulocyte-macrophage colony-stimulating factor for autologous transplantation in advanced breast cancer.
Ho AD; Glück S; Germond C; Sinoff C; Dietz G; Maruyama M; Corringham RE
Leukemia; 1993 Nov; 7(11):1738-46. PubMed ID: 7901454
[TBL] [Abstract][Full Text] [Related]
34. Phase I trial of high-dose melphalan, high-dose etoposide and autologous bone marrow re-infusion in solid tumors: an Eastern Cooperative Oncology Group (ECOG) study.
Lazarus HM; Gray R; Ciobanu N; Winter J; Weiner RS
Bone Marrow Transplant; 1994 Sep; 14(3):443-8. PubMed ID: 7994270
[TBL] [Abstract][Full Text] [Related]
35. Dose-intense paclitaxel, etoposide and cyclophosphamide: a safe and active regimen for tumor cytoreduction and stem cell mobilization in metastatic breast cancer.
Bilgrami S; Feingold JM; Bona RD; Edwards RL; Khan AM; Rodriguez-Pinero F; Khan IA; Kazierad D; Clive J; Tutschka PJ
Bone Marrow Transplant; 2000 Jan; 25(2):123-30. PubMed ID: 10673668
[TBL] [Abstract][Full Text] [Related]
36. High-dose carboplatin, etoposide and melphalan (CEM) with peripheral blood progenitor cell support as late intensification for high-risk cancer: non-haematological, haematological toxicities and role of growth factor administration.
Benedetti Panici P; Pierelli L; Scambia G; Foddai ML; Salerno MG; Menichella G; Vittori M; Maneschi F; Caracussi U; Serafini R; Leone G; Mancuso S
Br J Cancer; 1997; 75(8):1205-12. PubMed ID: 9099971
[TBL] [Abstract][Full Text] [Related]
37. Use of high-dose etoposide/ifosfamide/carboplatin/epirubicin and peripheral blood progenitor cell transplantation in limited-disease small cell lung cancer.
Brugger W; Frommhold H; Pressler K; Mertelsmann R; Kanz L
Semin Oncol; 1995 Feb; 22(1 Suppl 2):3-8. PubMed ID: 7531368
[TBL] [Abstract][Full Text] [Related]
38. Tandem high-dose chemotherapy supported by hematopoietic progenitor cells yields prolonged survival in stage IV breast cancer.
Bitran JD; Samuels B; Klein L; Hanauer S; Johnson L; Martinec J; Harris E; Kempler J; White W
Bone Marrow Transplant; 1996 Feb; 17(2):157-62. PubMed ID: 8640160
[TBL] [Abstract][Full Text] [Related]
39. Phase II study of high-dose cyclophosphamide, etoposide, and carboplatin (CEC) followed by autologous hematopoietic stem cell rescue in women with metastatic or high-risk non-metastatic breast cancer: multivariate analysis of factors affecting survival and engraftment.
Klumpp TR; Goldberg SL; Magdalinski AJ; Mangan KF
Bone Marrow Transplant; 1997 Aug; 20(4):273-81. PubMed ID: 9285541
[TBL] [Abstract][Full Text] [Related]
40. High-dose sequential chemotherapy with autologous blood stem cell rescue for relapsed or resistant lymphoma.
Sanna P; Van den Bosch S; Cavalli F; Ghielmini M
Schweiz Med Wochenschr; 1998 Oct; 128(40):1500-7. PubMed ID: 9888164
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]